Biomarker ID | 891 |
PMID | 22452941 |
Year | 2012 |
Biomarker | Methylation Status of CYP26A1 |
Biomarker Basis | Methylation Based |
Biomolecule | Methylation |
Source | Tissue |
Subjects | Humans |
Regulation | Highly methylated in ERG positive fusion compared to ERG negative fusion |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | ERG positive fusion compared to ERG negative fusion in Prostate cancer |
Type of Biomarker | Prognostic |
Cohort | 253 patients with prostate cancer, with 76 cases with Biochemical Recurrence. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p≤0.041 |
Method Used | ERG Fusion Status: Immunohistochemistry; Methylation Status: quantitative MethyLight assay |
Clinical | No |
Remarks | NA |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | CYP26A1 |